tbuckley/cabot-search huggingface dataset:
Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study.
Authors: Y Kaneko, N Kanda, N Maseki, K Nakachi, T Takeda, I Okabe, M Sakurai
Journal: Journal of Clinical Oncology (1990)

We studied 96 infants and children with untreated neuroblastomas. Chromosomes of tumor cells were analyzed in 68, and N-myc copy numbers were determined in 67 patients. Patients found by a mass screening program for 6-month-old infants (group A1, 39 patients) or those less than 12 months of age found clinically (group A2, 13 patients) were rarely in the disseminated stage (A1, three of 39; A2 one of 13); their tumors usually had near-triploid (3n) or hypertetraploid (greater than 4n) karyotypes (A1, 28 of 37; A2, nine of 11), and never had N-myc amplification (A1, zero of 34; A2, zero of 11). In contrast, children 12 months or over (group B, 27 patients) were usually in the disseminated stage (19 of 27) (P less than .0001); their tumors usually had near-diploid (2n) or near-tetraploid (4n) karyotypes (16 of 20) (P = .0027), and often had N-myc amplification (nine of 22) (P less than .0001). Of the 40 clinically found patients (A2 and B), six had undergone the screening with a negative result at the age of 6 months. Two of the six patients had N-myc amplification in the tumors. Most tumors found by the screening showed known characteristics predicting a good prognosis, and the majority of tumors showing characteristics predicting a poor prognosis were found in patients aged between 12 and 36 months. Our chromosome and N-myc amplification studies suggest that a low-risk tumor does not usually evolve to a high-risk tumor. Thus, the current mass screening program may be detecting only a small portion of highly malignant neuroblastomas at the earliest stage. Infants should be screened twice, at 6 months as well as at 12 months of age, for the early detection of high-risk neuroblastomas.
Preoperative MRI: Much ado about nothing?
Authors: Sarah P. Cate, Pamela Li, John Rescigno, Manjeet Chadha, Alyssa Gillego, Susan K. Boolbol
Journal: Journal of Clinical Oncology (2014)

16 Background: Preoperative MRI has been used to identify mammographically occult lesions and to determine extent of disease. However, the role of preoperative MRI in breast cancer remains controversial. We previously found that preoperative MRI does not increase total mastectomy (TM) rate. In this study we sought to identify a specific subgroup of patients in which preoperative MRI may be useful. Methods: In this IRB approved study, we conducted a retrospective review of 257 patients with breast cancer who underwent preoperative MRI from 2010 to 2012. We evaluated whether additional imaging and biopsies were recommended after MRI and whether it influenced the final surgical plan and decreased re-excision rate after partial mastectomy (PM). We collected data on several clinical factors and tested these for significant associations with both upgrading to TM and with the need for post-MRI imaging and biopsy using crosstab analysis and Fisher’s Exact test. Age as a continuous variable was also evaluated using binary logistic regression. Results: In our study cohort, 158 patients (62%) had additional imaging and 78 patients (30%) had additional biopsies recommended based on the MRI report. Of those biopsies prompted by MRI, 32 of them (39%) revealed cancer. The clinical significance, however, is subject to further study as only 3% of the 257 patients, eight upgraded to TM. We did not find any statistically significant differences in patients who were upgraded to TM by clinical factors such as age, menopausal status, mammographic breast density, ER/PR, HER2/neu status, or pathologic T stage; though there was a trend towards upgrade to TM in those who required additional imaging (p = 0.16). We found no clinical factors associated with the need for additional biopsies. Conclusions: We did not find a specific subgroup of patients in which preoperative MRI influenced management. Although preoperative MRI slightly increased the rate of TM, it does lead to numerous additional imaging studies and biopsies. Given these results, we are no longer using preoperative MRI routinely at our institution. Additional studies will be needed to determine strict indications for the use of MRI in the preoperative setting.
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS)
Authors: G. Mantovani, C. Madeddu, G. Gramignano, M. R. Lusso, E. Massa, R. Serpe, L. Deiana, M. Dessì, A. Macciò, G. Astara
Journal: Journal of Clinical Oncology (2005)

8195 Background: A phase II non randomized study has been designed to enroll 39 advanced cancer patients with symptoms of CACS/OS to evaluate the efficacy and tolerability of an innovative approach consisting of: diet with high polyphenols content (400 mg), oral pharmaco-nutritional support enriched with n-3 PUFA (EPA, DHA) 2 cans/day, medroxyprogesterone acetate 500 mg/day, antioxidant treatment (alpha lipoic acid 300 mg/day + carbocysteine lysine salt 2.7 g/day + vitamin E 400 mg/day + vitamin A 30000 IU/day + vitamin C 500 mg/day), selective COX-2 inhibitor Celecoxib 200 mg/day. Patients and Methods: 34 patients with advanced tumors at different sites (mainly head and neck and lung)have been enrolled. The treatment duration was 16 weeks. The following parameters have been evaluated: 1) clinical (objective clinical response and ECOG PS); 2) nutritional (Lean Body Mass, LBM, appetite and resting energy expenditure, REE); 3) laboratory (proinflammatory cytokines and leptin, reactive oxygen species (ROS) and antioxidant enzymes); 4) quality of life (EORTC QLQ- C30, EQ-5D and MFSI-SF). Results: At November 2004 29 patients are evaluable. LBM increased 1.1 kgs (+3.7%, N.S.) after 1 month, 1.6 kgs (+7.0%, p=0.035) after 2 months and 1.9 kgs (+8.7%, p=0.049) after 4 months. Appetite increased significantly after 1, 2 and 4 months of treatment. The REE studied in 3 patients decreased after 4 months of treatment. The serum levels of proinflammatory cytokines IL-6 and TNFalpha significantly decreased during treatment. As for QL evaluation, the EORTC QLQ-C30, EQ-5D and MSFI-SF scores significantly improved after 1, 2 and 4 months of treatment. The interim analysis on 29 patients currently evaluable shows 16 responses (12 “responders” and 4 “high responders”). Conclusion: According to the 2 stage Simon’s design criteria for Phase II studies the treatment is to be considered effective. Moreover, the treatment has demonstrated to be safe. The study is in progress to complete the accrual. Work Supported by: Italian Ministry of University and Scientific Research, Rome, Italy: National Research Project No. 2004067078. No significant financial relationships to disclose.
Randomized Phase Ii Trial with Dendritic Cell (Dc) Immunotherapy in Patients with Colorectal Carcinoma and Liver Metastasis Following Complete Resection and Adjuvant Chemotherapy
Authors: J. Rodriguez, R. Vera, F. Pardo, J. Herrera, A. Chopitea, C. Alfaro, I. Hernández García, C. Garzón, A. Viudez Berral, A. Benito, A. Gonzalez, M.E. RodrÍguez-Ruiz, M. Fernandez de Sanmamed, J.P. Fusco, C. Oñate, C. Ochoa, I. Melero, J.L. Perez Gracia
Journal: Annals of Oncology (2014)
A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies
Authors: Stephen Couban, Mahmoud Aljurf, Silvy Lachance, Irwin Walker, Cynthia L. Toze, Morel Rubinger, Jeff H. Lipton, Stephanie J. Lee, Jeffrey Szer, Richard Doocey, Ian D Lewis, Lothar B. Huebsch, Kang Howson-Jan, Faisal Al Mohareb, Naeem Chaudhri, Aminia Kariminia, Sabine Ivison, Diane L. Fairclough, Gerald Devins, David Szwajcer, Stephen Ronan Foley, Clayton A. Smith, Tony Panzarella, Holly Margaret Kerr, Kirk R. Schultz
Journal: Blood (2013)
Predictive value for thrombosis of pre-chemotherapy D-Dimer in ambulatory cancer patients
Authors: E. Vicente, E. Gonzalez-Billalabeitia, M. Zafra, E. García-Martinez, V. Roldan, T. García, J. Lopez-Oliva, J. Macias, V. Vicente, F. Ayala
Journal: Journal of Clinical Oncology (2009)

e20601 Background: Elevated D-Dimer (DD) is related with activated coagulation system. We pretended to assess if high DD is predictive of thrombosis in ambulatory cancer patients. Methods: We prospectively determined DD in plasma specimens from ambulatory cancer patients, without previous thromboembolic events (TE), before chemotherapy initiation. DD was determined with an immunological test in an automated coagulometer (IL D-Dimer test, Instrumentations laboratory). The selected cut-off point for DD was 1.5 x UNL, as it was the nearest point to the median DD. All thromboembolic events were recorded. Results: Between June 2007 and December 2008 eighty four patients were included, 66% with advanced and 34% with early disease. The most frequent tumours were colorectal 31%, breast 27% and genitourinary cancers 30% (12% HR prostate and 28% non prostate cancers). Antiangiogenic drugs were included in 24% of treatments (16% Bevacizumab and 8% Sunitinib). Median ECOG was 1. With a median follow-up of 6.5 months, 12 thromboembolic events were observed (5 PE, 3 DVT and 4 Arterial thrombosis). The following variables were included in the univariate analysis: high DD (&gt;1.5 x UNL), low haemoglobin (Hb &lt;10 mg/dL), high leukocyte, high platelet, high BMI and tumour location. High DD (HR = 6,25, 95% CI: 1,34–29,25; p= 0,02) and low Hb (HR= 6,17, 95% CI: 1,77- 21,53; p=0,004) were associated with increased TE. The high risk group in the Khorana index was also significant (p=0.02). In multivariate analysis both high DD (HR= 5,06, 95%CI: 1,05–24,48; p=0,044) and low Hb (HR=3,77, 95%CI: 1,02–13,97; p=0,047) remained significant. Conclusions: High pre-chemotherapy DD is associated with increased risk of thrombosis in ambulatory cancer patients. No significant financial relationships to disclose.
Paracetamol induced liver failure varies widely across Europe, study finds
Authors: S. Mayor
Journal: BMJ (2015)

The rate of acute liver failure induced by paracetamol is much higher in some European countries than in others, with no clear reason for the variation, a study has found. Paracetamol overdose was found to account for one in six cases of acute liver failure that lead to registration for transplantation.

Researchers identified all cases of acute liver failure from liver transplant registries in France, Greece, Ireland, Italy, the Netherlands, Portugal, and the United Kingdom over a three year …
The benefits of a restaging PET scan after two cycles of neoadjuvant chemotherapy for resectable non-small cell lung cancer
Authors: T. Tanvetyanon, E. Eikman, L. Robinson, E. Sommers, A. Cantor, G. Bepler
Journal: Journal of Clinical Oncology (2006)

17092 Background: Neoadjuvant chemotherapy can potentially improve the outlook of resectable non-small cell lung cancer (NSCLC). Whole-body 2-deoxy-2-[18F] fluoro-D-glucose (FDG)-PET is often used as an initial test to determine tumor resectability, but its role as a restaging test after neoadjuvant chemotherapy is unclear. Restaging PET after neoadjuvant chemoradiation helps identify unexpected distant metastasis and avoid unnecessary thoracotomy. We explored its benefits after neoadjuvant chemotherapy. Methods: Patients with stage IB-IIIA and selected IIIB resectable NSCLC received induction gemcitabine (1,000 mg/m 2 ) and vinorelbine (25 mg/m 2 ) on days 1, 8, 22, and 29. PET and CT scan were performed before enrollment and between day 43–50. Response from CT scan was defined by RECIST criteria; from PET, defined as &gt;20% reduction in the SUVmax (a decrease of &gt; 2 SD of spontaneous change in FDG uptake, previously validated). This abstract explores patients participated in a published prospective trial with available both pre- and post-treatment PET scans. Results: There were 19 patients: stage IB-7, stage IIB-2, and stage III-10. Median age was 67 years. Mean interval between staging and restaging PET scan was 59 days. By PET, 10 patients responded. By RECIST criteria, complete response occurred in 0, partial response in 6, and stable disease in 13 patients. Most successfully underwent a complete resection, but positive margins were present in 3; multi-station lymph node involvement was found intraoperatively in 1 patient. Overall median survival was 20.5 months. We found that restaging PET did not help identify any distant metastasis. Moreover, no survival difference was observed between PET responders and non-responders, though PET responders had more advanced stage than their counterparts: median survival 16 months vs. not reached (p = 0.08 adjusted for stage). PET response was correlated with RECIST response (p = 0.05) as well as the response as obtained by SUV max divided by the activity of contralateral lung or aorta ratio. Conclusion: Based on this small group of patients, a restaging PET scan obtained after two cycles of neoadjuvant chemotherapy among patients with resectable NSCLC did not appear to impact the decision on a planned thoracotomy. No significant financial relationships to disclose.
Abstract 11976: Left ventricular Mass in Young Healthy Adults Predicts 20-year Clinical Cardiovascular Events Beyond the Global Cardiovascular Framingham 10 Year Risk Score: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Authors: Anderson C Armstrong, Samuel S Gidding, Laura A Colangelo, Ola Gjesdal, Kiang Liu, Cora E Lewis, Kirsten Bibbins-Domingo, Stephen Sidney, Pamela J Schreiner, David R Jacobs, O. D Williams, David C Goff, Joao AC. Lima
Journal: Circulation (2012)

Anderson C Armstrong, 2012 Finalist and Presenting Author
Preliminary report of psychiatric disorders in survivors of a severe earthquake
Authors: P Sharan, G Chaudhary, S A Kavathekar, S Saxena
Journal: American Journal of Psychiatry (1996)

The authors' goal was to study psychiatric morbidity after a natural disaster in rural India.As members of a volunteer medical team assigned to 23 households in three villages in India affected by an earthquake, the authors examined the results of semi-structured interviews used to interview all of the adults (older than 14 years) in these households (N=56). DSM-III-R diagnoses were assigned on the basis of these interviews, and non-parametric tests were applied to comparisons of subjects who were or were not given a psychiatric diagnosis.Thirty-three (59%) of the subjects received a psychiatric diagnosis; the most common diagnoses were posttraumatic stress disorder (13 subjects [23%]) and major depression (12 subjects [21%]). Psychiatric morbidity was associated with female sex, destruction of house, and destruction of possessions.Attention to the mental health needs of disaster survivors in third world countries is indicated.
Abstract 19036: Transgenic Mouse with Overexpression Hypoxamir-210: Implications on Infarct Size Attenuation and Preservation of Heart Function
Authors: Rafeeq P Ahmed, Shujia Jiang, Christy Caudil, Shazia Durrani, Khawaja Haider
Journal: Circulation (2012)

Background. Hypoxamir-210 (miR-210) is a universal responder to activation of HIF-1 signaling and plays a significant role in cell survival under ischemic stress. To assess the impact of constitutive over expression of hypoxamir-210 on infarct size expansion and preservation of cardiac function, we report the development of first transgenic (TG) mouse model with miR-210 overexpression ( 210 TG). Methods and Results. miR-210 transgenic mouse was generated at the University of Cincinnati transgenic core using the C57BL/6 mouse strain. Briefly precursor miR-210 along with H1 promoter (HmiR0167-MR01 vector from Genocopiea) was amplified and cloned into pShuttle vector (Stratagene) using restriction enzymes Not1 and Sal1. Amplified vector was digested, purified and used for microinjection into the pronuclei of single cell embryos derived from superovulated C57BL/6 females. The surviving embryos were implanted into foster female mice. TG mice were identified genotyping of the tail genomic DNA by PCR. As compared to control littermates (NTG), 210 TG had significantly higher miR-210 expression in different tissues and organs including the heart and the bone marrow. Molecular studies showed altered expression of miR-210 putative traget Dffb in 210 TG animals. Age and sex-matched mouse model of permanent LAD coronary artery ligation was developed in 210 TG(n=12 animals/group) using NTGas controls. Animals were harvested on day 7 (short term) and 28 (long term) after LAD ligation. Echocardiography performed prior to euthanasia showed that cardiac function was significantly preserved in 210 TG as compared to NTG as indicated by LVEF (45.2±1.06 vs 38.9±1 p &lt;0.001) and LVFS (18.3±1 vs 15±1), Histochemical studies showed preserved myocardial architecture and attenuated infarct size in 210 TG ( p &lt;0.05 vs NTG). TUNEL combined with fluorescence immunostaining for cardiac troponin-1, smooth muscle actin and CD31 showed significantly reduced TUNEL positivity of cardiomyocytes, smooth muscle and endothelial cells in 210 TG heart at day 7 ( p &lt;0.05 vs NTG hearts). Conclusions. Constitutive overexpression of hypoxamir-210 rescued global cardiac function after myocardial infarction by inhibition of cardiomyocyte apoptosis to attenuate infarct size in the heart.
Abstract 16310: Differential Activation of HIF1-{alpha} is Associated with Reduced Arteriogenesis After Hind Limb Ischemia in PCAF-/- Mice
Authors: Teun Bastiaansen, Mark Ewing, Hetty de Boer, Tineke van der Pouw Kraan, Margreet de Vries, Erna Peters, Ramon Arens, Scott Moore, James Faber, Wouter Jukema, Jaap Hamming, Paul Quax, Anne Yael Nossent
Journal: Circulation (2012)

Although arteriogenesis is generally considered to be a shear stress-driven process, hypoxia-inducible factor-1α (HIF-1α) has a strong stimulatory effect on arteriogenesis. Recently, it was shown t...
Autologous bone marrow transplantation in childhood cancer.
Authors: J V Simone
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.8.1439 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8336182 Autologous bone marrow transplantation in childhood cancer. J V SimonexJ V SimoneSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.8.1439 PDF "Autologous bone marrow transplantation in childhood cancer.." Journal of Clinical Oncology, 11(8), pp. 1439–1440© 1993 by American Society of Clinical Oncology
Time to recurrence and survival in triple negative early-stage breast cancer
Authors: R. Gerson, A. Villalobos, L. Alban, A. Serrano
Journal: Journal of Clinical Oncology (2007)

21151 Background: Breast cancer (BC) is the most common neoplasm among Mexican women. Clinical, tumoral and biologic factors have proven useful in predicting prognosis regarding recurrence and survival. Triple negative (TN) phenotype (ER, PR and HER2 negative) has been reported to be associated with more aggressive clinical behavior. Objective: To compare clinical, tumor, biologic characteristics of TN time to recurrence and survival to other phenotypes in early BC. Methods: Records of women with stage I - II BC evaluated from Jan. 2000 to June 2006 were reviewed. ER/PR+: &gt; 10 fmol/pgr and HER2+, 3+ by immunohistochemistry or FISH &gt; 2.2 were considered. Five groups were designed: 1) TN, 2) triple positive, 3) HER2-/ER/PR+, 4) HER2+/ER/PR-, 5) HER2-/ one hormonal receptor (HR) +. ANOVA, Chi-2 and Kruskal-Wallis tests were applied for the statistical analysis. Results: 110 patients were included (17, 14, 52, 11, 16 respectively). Median age (43, 49.5, 55, 53 51 yrs); clinical stage; tumor size, axillary lymph node status and angiogenesis score were similar in all groups, p &gt; 0.05. Median Ki67 was higher in TN group (47.5, 20, 20, 42.5, 10, p&lt; 0.000). Proportion of patients with conservative surgery was similar, p= 0.308. Fourteen recurrences were observed, 2 local and 12 systemic (3, 1, 3, 5, 2 in each group). Median time to recurrence (6, 54, 30, 20, 27 mos); there were 7 deaths due to tumor. Number of deaths was higher in TN and HER+/HR- (17.4, 7.1, 0, 18.1, 6.2%). Conclusions: TN phenotype represents 15% in this early BC population and was associated to higher Ki67. There are premature signs (age, number of recurrences and deaths) that suggest a poor prognosis for TN patients, similar to those with HER2+/ERPR- . No significant financial relationships to disclose.
A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel
Authors: J. Ang, C. Mikropoulos, F. Stavridi, S. Rudman, M. Uttenreuther-Fisher, M. Shahidi, K. Pemberton, S. Wind, J. de Bono, J. F. Spicer
Journal: Journal of Clinical Oncology (2009)

e14541 Background: BIBW 2992 is an oral, potent and irreversible inhibitor of both EGFR and HER2 receptor tyrosine kinases. The efficacy of cytotoxic agents can be enhanced by erbB inhibition. The primary objective of this Phase I open- label dose-escalation trial was to determine the maximum tolerated dose (MTD) of BIBW 2992 in combination with weekly paclitaxel. Methods: This study evaluated safety, pharmacokinetics (PK), and anti-tumor efficacy of daily BIBW 2992 combined with paclitaxel administered on Days 1, 8 and 15 of a 4-weekly cycle. The dose of paclitaxel was 80 mg/m 2 , and the BIBW 2992 starting dose was 20 mg, escalated in successive cohorts to 40 then 50 mg. After 6 cycles of combination therapy, patients benefiting and tolerating treatment were eligible to continue single agent BIBW 2992. Results: Sixteen patients with advanced solid tumors expressing erbB receptors and suitable for treatment with a taxane have been enrolled (6 male/10 female; median age: 59 [range: 39–72]; ECOG PS 0/1: 5/11). Two dose-limiting toxicities of fatigue and mucositis occurred at a BIBW 2992 dose of 50 mg. The most frequent adverse events were fatigue, rash, mucositis and diarrhea. Partial responses were seen in patients with non-small cell lung cancer (3), prostate cancer (1), oesophageal cancer (1) and cholangiocarcinoma (1). Eight patients have remained on treatment beyond 4 cycles. The PK data of paclitaxel (with and without BIBW 2992 administration) as well as of BIBW 2992 at steady state (in combination with paclitaxel) will be described. Conclusions: A BIBW 2992 dose of 40 mg daily in combination with weekly paclitaxel 80 mg/m 2 is the likely recommended dose for Phase II study. Promising anti-tumor activity was seen with this combination. The addition of bevacizumab to BIBW 2992 with 80 mg/m 2 weekly paclitaxel is now being evaluated. Adverse events of BIBW 2992 combined with paclitaxel were generally mild to moderate and manageable. [Table: see text]